P

Peak Gastroenterology Associates | Peak Gastro Colorado Springs

Research site
(Unclaimed)
Location
2920 N Cascade Avenue, Colorado Springs, Colorado, United States of America
Site insights

Top conditions

Ulcer (16 trials)

Ulcerative Colitis (16 trials)

Colitis (16 trials)

Crohn Disease (13 trials)

Non-alcoholic Fatty Liver Disease (7 trials)

Top treatments

Etrasimod
Guselkumab
Relamorelin
Ontamalimab
APT-1011
Ozanimod
Etrolizumab
CC-93538
Golimumab
Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

22 of 54
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (E...

Active, not recruiting
Eosinophilic Esophagitis
Procedure: Esophagogastroduodenoscopy
Drug: Placebo oral tablet

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling
Primary Biliary Cholangitis (PBC)
Other: Matched 80 mg placebo
Drug: Elafibranor

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod
Other: Placebo

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabol...

Enrolling
Eosinophilic Esophagitis
Drug: CYP substrates
Drug: Cendakimab
Locations recently updated

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Etrasimod
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)

Enrolling
Coeliac Disease
Celiac Disease
Drug: KAN-101
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Enrolling
Colitis, Ulcerative
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling
Primary Sclerosing Cholangitis
Drug: Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 80 mg

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo
Locations recently updated

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Enrolling
Ulcerative Colitis
Drug: Etrasimod

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult...

Active, not recruiting
Ulcerative Colitis
Drug: Placebo
Drug: Etrasimod

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

Trial sponsors

Celgene logo

Celgene (7 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems